KW-2449

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameKW-2449
Drug Alias NameKW-2449
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora inhibitorsBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors +[4] 
TargetsBcr-Abl tyrosine kinaseSerine/threonine-protein kinase AuroraTyrosine-protein kinase receptor FLT3 +[4] 
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKyowa Kirin IncKyowa Kirin Co LtdKyowa Hakko Kirin Co Ltd
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute +[5] 

Other Information

ATC CodeN/A
Related LinksN/A